Shareholders to Vote on Massive Dilution, Reverse Split, and Share Increase to Avert Delisting and Address Debt

summarizeSummary

Gossamer Bio is seeking shareholder approval for highly dilutive measures, including a massive share increase and a reverse stock split, to address its distressed debt and avoid Nasdaq delisting.

check_boxKey Events · Financing and Capital Events · GOSS

• Shareholder Vote on Distressed Debt Exchange Dilution

  Shareholders will vote on approving the potential issuance of shares upon conversion of up to $72.0 million in New Convertible Notes and exercise of 135,789,000 Purchase Warrants. This is part of a distressed debt exchange, with early settlement already completed for $181.05 million of existing notes. If all shares and warrants are issued, existing noteholders would own approximately 78.7% of the pro forma outstanding common stock, resulting in substantial dilution for current shareholders.

• Proposed Increase in Authorized Shares

  The company is seeking approval to increase its authorized common stock from 700,000,000 to 4,000,000,000 shares. This increase is necessary to support the massive share issuances related to the debt exchange and a new equity incentive plan.

• Reverse Stock Split to Avoid Delisting

  Shareholders will vote on authorizing the Board to effect a reverse stock split at a ratio between 1-for-10 and 1-for-150. This measure is critical to regain compliance with Nasdaq's minimum $1.00 bid price requirement, as the company received a delisting notice on April 8, 2026, and is currently trading near its 52-week low.

• New Equity Incentive Plan Proposed

  Approval is sought for an amended and restated 2019 Incentive Award Plan to increase the number of shares available for equity awards. This is a direct consequence of the substantial dilution from the debt exchange, which has diluted existing equity awards and necessitates more shares to retain key personnel.

auto_awesomeAnalysis · GOSS · Life Sciences

This definitive proxy statement outlines critical proposals for Gossamer Bio's survival, following a series of adverse events including a failed Phase 3 trial, a going concern warning, and a Nasdaq delisting notice. Shareholders are being asked to approve measures that will result in substantial dilution (up to 78.7% of pro forma outstanding shares) to restructure debt and enable the company to continue operations. The proposed reverse stock split is a direct response to the Nasdaq minimum bid price deficiency, aiming to prevent delisting. Failure to approve these proposals could lead to insolvency or bankruptcy, making this a pivotal vote for the company's future.